Amphastar Pharmaceuticals, Inc. and Xencor, Inc.: SG&A Spending Patterns Compared

Amphastar vs. Xencor: SG&A Spending Trends Unveiled

__timestampAmphastar Pharmaceuticals, Inc.Xencor, Inc.
Wednesday, January 1, 2014403730007461000
Thursday, January 1, 20154697400011960000
Friday, January 1, 20164729800013108000
Sunday, January 1, 20175091800017501000
Monday, January 1, 20185804400022472000
Tuesday, January 1, 20196310900024286000
Wednesday, January 1, 20206515700029689000
Friday, January 1, 20216892000038837000
Saturday, January 1, 20226659200047489000
Sunday, January 1, 20238039300053379000
Loading chart...

Data in motion

SG&A Spending Trends: Amphastar vs. Xencor

In the competitive landscape of pharmaceuticals, understanding spending patterns is crucial. Over the past decade, Amphastar Pharmaceuticals, Inc. and Xencor, Inc. have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. Amphastar's SG&A expenses have surged by approximately 99% from 2014 to 2023, reflecting a strategic expansion and investment in operational capabilities. In contrast, Xencor's expenses have increased by over 600% during the same period, indicating a rapid scale-up in their administrative and sales efforts. Notably, Amphastar consistently outspent Xencor, with 2023 figures showing Amphastar's expenses at 50% higher than Xencor's. This divergence highlights differing growth strategies and market positioning. As the pharmaceutical industry continues to evolve, these spending patterns offer insights into each company's priorities and future directions.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025